Pfizer announced Thursday that a third shot of its COVID-19 vaccine raised omicron-fighting antibody by 36 times in children ages 5 to 11.
Pfizer/BioNTech plans to request emergency use authorization from the FDA for a booster vaccine for this age group in the coming days.
The study looked at 140 children between 5 and 11 years old.
The children were administered a 10-microgram dose of the booster shot six months after their second dose.
That’s a smaller dose than what is administered to adults, which is 30 micrograms.
Omicron-fighting antibodies increased 36-fold from the levels recorded after the second dose of the Pfizer vaccine.
Antibodies levels against the original coronavirus strain increased 6-fold with the booster shot.
Scientists outside of Pfizer/BioNTech have not yet reviewed the new data.
The CDC has said that the spread of the omicron variant has led to a record number of COVID-19 cases in children, compared to other variants.
However, fewer than one-third of children in this age group have received two full of a COVID vaccine, according to CDC data.